Skip to main content
PBH logo

PBH · Prestige Consumer Healthcare Inc. · Financials

Track PBH — free
$49.46 +1.54 (+3.21%)
Market Cap
$2.27B
Shares
47.37M
Volume · Oct 22 660.92K Avg daily vol (3M) 555.17K

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Revenue
$1.09B -4.3%
FY2026 Revenue FY2010–FY2026
Net Income
$190.3M -11.3%
FY2026 Net Income FY2010–FY2026
Gross Margin
54.71% -1pp
FY2026 Gross Margin FY2010–FY2026
Operating Margin
28.42% -1.2pp
FY2026 Operating Margin FY2010–FY2026
Diluted EPS
$3.91 -8.9%
FY2026 Diluted EPS FY2010–FY2026
Operating Cash Flow
$257.63M +2.4%
FY2026 Operating Cash Flow FY2010–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item FY2027 (G) TTM FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010
$1.29B – $1.32B $1.1B $1.09BG $1.14BG $1.13BG $1.13BG $1.09BG $943.37MG $963.01M $975.78M $1.04B $882.06M $806.25M $713.46M $595.64M $616.92M $441.09M $336.51M $292.6M
— — -$42.34M -$47.63M -$67.16M -$69.16M -$64.29M — — — — — — — — — — — —
— $513.45M $493.13M $503.3M $500.91M $502.43M $466.17M $395.89M $410.79M $420.2M $464.67M $381.77M $339.04M — — — — — —
— $591.44M $595.58M $634.46M $624.45M $625.29M $620.65M $547.47M $552.22M $555.58M $576.51M $500.29M $467.21M $406.22M $335.55M $343.74M $227.38M $170.88M $153.44M
— — 54.71% 55.76% 55.49% 55.45% 57.11% 58.03% 57.34% 56.94% 55.37% 56.72% 57.95% 56.94% 56.33% 55.72% 51.55% 50.78% 52.44%
— $131.29M $116.45M $108.21M $106.15M $107.35M $107.46M $83.11M $89.11M $89.76M $85.39M $89.11M $72.42M $81.27M $48.48M $51.47M $56.7M $41.96M $34.2M
— $18.35M $17.92M $18.26M $19.78M $22.27M $21.5M $19.58M $19.63M $21.77M $23.35M $19.75M $18.43M $13M $10.26M $11.68M $9.99M $9.21M —
— $32.36M $31.27M $30.17M $30.68M $32.63M $32.09M $30.16M $29M $31.78M $33.43M $25.79M $23.68M $17.74M $13.49M $13.24M $10.73M $10.11M $11.45M
— $301.26M $286.17M $297.69M $282.02M $647.71M $290.73M $250.07M $261.07M $488.07M $361.03M $294.64M $206.9M $198.66M $146.94M $151.85M $124.56M $94.73M $75.12M
— $290.17M $309.41M $336.78M $342.43M -$22.42M $329.92M $297.4M $291.16M $67.5M $215.47M $205.64M $260.32M $207.56M $188.62M $191.88M $102.82M $76.15M $78.33M
— — 28.42% 29.6% 30.43% -1.99% 30.36% 31.53% 30.23% 6.92% 20.7% 23.31% 32.29% 29.09% 31.67% 31.1% 23.31% 22.63% 26.77%
— $322.53M $340.68M $366.95M $373.1M $10.21M $362.01M $327.57M $320.15M $99.28M $248.9M $231.44M $283.99M $225.3M $202.1M $205.12M $113.56M $86.25M $89.78M
— — — $1.8M $5.2M $4.4M — — — — — — — — — — — — —
— — — — — — — — $342K $217K $388K $203K $162K $92K $60K $13K $18K $1000 $1000
— -$9.83M -$9.57M -$4.95M $756K -$2.34M -$1.05M $1.37M -$1.63M -$476K $392K -$30K — — — — — — —
— — $257.5M $284.19M $276.03M -$93.92M $262.46M $204.11M $191.15M -$38.06M $107.09M $110.85M $157.19M $127.46M $101.75M $106.03M $61.16M $48.53M $52.73M
— $62.25M $67.2M $69.58M $66.69M -$11.61M $57.08M $39.43M $48.87M -$2.26M -$232.48M $41.46M $57.28M $49.2M $29.13M $40.53M $23.95M $19.35M $20.66M
— $172.01M $190.3M $214.61M $209.34M -$82.31M $205.38M $164.68M $142.28M -$35.8M $339.57M $69.4M $99.91M $78.26M $72.62M $65.51M $37.21M $29.22M $32.12M
— — 17.48% 18.86% 18.6% -7.3% 18.9% 17.46% 14.77% -3.67% 32.61% 7.87% 12.39% 10.97% 12.19% 10.62% 8.44% 8.68% 10.98%
— $174.59M $199.59M $211.44M $206.41M -$94.84M $206.15M $189.04M $123.87M -$42.23M $346.61M $66.57M $99.79M $54.11M $73.46M $65.41M $37.2M $29.22M $33.45M
USD/shares — $3.58 $3.93 $4.32 $4.21 -$1.65 $4.09 $3.28 $2.81 -$0.69 $6.40 $1.31 $1.89 $1.50 $1.41 $1.29 $0.74 $0.58 $0.64
USD/shares $4.55 – $4.65* $3.57 $3.91G $4.29 $4.17G -$1.65G $4.04G $3.25G $2.78G -$0.69 $6.34 $1.30 $1.88 $1.49 $1.39 $1.27 $0.73 $0.58 $0.64
shares — — 48.46M 49.7M 49.76M 49.89M 50.26M 50.21M 50.72M 52.07M 53.1M 52.98M 52.75M 52.17M 51.64M 50.63M 50.27M 50.08M 50.01M
shares — — 48.72M 50.08M 50.18M 49.89M 50.84M 50.61M 51.14M 52.07M 53.53M 53.36M 53.14M 52.67M 52.35M 51.44M 50.75M 50.34M 50.09M
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2013–FY2026: $401.36M in buybacks, $0 in dividends.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Current portion of line of credit borrowings 2026-06-30 USD 3,639,000 10-Q filed 2026-08-06
Current portion of long-term debt 2026-06-30 USD 10,450,000 10-Q filed 2026-08-06
Finance lease liabilities 2026-06-30 USD 19,975,000 10-Q filed 2026-08-06
Related accounting measures — not additional borrowing

Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.

Current finance lease liabilities
USD 2,699,000
Noncurrent finance lease liabilities
USD 17,276,000
Noncurrent debt carrying amount 2026-06-30 USD 2,007,235,000 10-Q filed 2026-08-06
Operating lease liabilities 2026-06-30 USD 26,139,000 10-Q filed 2026-08-06
Related accounting measures — not additional borrowing

Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.

Current operating lease liabilities
USD 7,010,000
Noncurrent operating lease liabilities
USD 19,129,000
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
1 filing has incomplete source or extraction coverage. Verified observations are shown; missing observations do not establish that debt was unchanged.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

6.250% senior notes due 2034

Note · Prestige Brands, Inc.

Reference: 6.250% senior notes due 2034

Active
Original principal
USD 400,000,000
Outstanding
—
Commitment
—
Availability
—
Maturity
Jul 15, 2034

Last reported interest terms: 6.25% Reported 2026-07-15 Later filings may not restate these terms; this does not confirm they still apply.

Covenant terms for this agreement are not yet verified.

Documents and filing history
  1. Issuance · 2026-07-15 Original principal USD 400,000,000 Exact source document Parent 8-K filing · 2026-07-15
    On July 15, 2026, Prestige Brands, Inc. (“Prestige Brands”), a wholly owned subsidiary of Prestige Consumer Healthcare Inc. (the “Company”), issued $400.0 million aggregate principal amount of 6.250% senior notes due 2034 (the “2026 Notes” or “notes”) pursuant to an Indenture, dated July 15, 2026 (the “Indenture”), among Prestige Brands, the guarantors party thereto (including the Company) and U.S. Bank Trust Company, National Association, as trustee. The Indenture provides, among other things, that interest will be payable on the notes on January 15 and July 15 of each year, beginning on January 15, 2027, until their maturity date of July 15, 2034. The notes are senior unsecured obligations of Prestige Brands and are guaranteed on an unsecured senior basis by the Company and certain of its existing and future domestic restricted subsidiaries.
    Issuer evidence: On July 15, 2026, Prestige Brands, Inc. (“Prestige Brands”), a wholly owned subsidiary of Prestige Consumer Healthcare Inc. (the “Company”), issued $400.0 million aggregate principal amount of 6.250% senior notes due 2034 (the “2026 Notes” or “notes”) pursuant to an Indenture, dated July 15, 2026 (the “Indenture”), among Prestige Brands, the guarantors party thereto (including the Company) and U.S. Bank Trust Company, National Association, as trustee. The Indenture provides, among other things, that interest will be payable on the notes on January 15 and July 15 of each year, beginning on January 15, 2027, until their maturity date of July 15, 2034. The notes are senior unsecured obligations of Prestige Brands and are guaranteed on an unsecured senior basis by the Company and certain of its existing and future domestic restricted subsidiaries.
    Supporting evidence: On July 15, 2026, Prestige Brands, Inc. (“Prestige Brands”), a wholly owned subsidiary of Prestige Consumer Healthcare Inc. (the “Company”), issued $400.0 million aggregate principal amount of 6.250% senior notes due 2034 (the “2026 Notes” or “notes”) pursuant to an Indenture, dated July 15, 2026 (the “Indenture”), among Prestige Brands, the guarantors party thereto (including the Company) and U.S. Bank Trust Company, National Association, as trustee. The Indenture provides, among other things, that interest will be payable on the notes on January 15 and July 15 of each year, beginning on January 15, 2027, until their maturity date of July 15, 2034. The notes are senior unsecured obligations of Prestige Brands and are guaranteed on an unsecured senior basis by the Company and certain of its existing and future domestic restricted subsidiaries.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
3.80×
Peer median 2.09×
EV/EBIT
14.47×
Peer median 18.72×
P/E (TTM)
13.42×
Peer median 17.14×

Peer medians compare against the 43 similar-size Drug Manufacturers - Specialty & Generic companies (of 101 listed).

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
North American OTC Healthcare $913,576,000 $960,010,000 $958,260,000 $973,774,000 $967,881,000 $849,319,000 $859,368,000 $862,446,000
International OTC Healthcare $175,129,000 $177,752,000 $167,097,000 $153,951,000 $118,931,000 $94,046,000 $103,642,000 $93,520,000
Household Cleaning — — — — — — — $19,811,000

By Geography (USD)

Component FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
United States $850,414,000 $897,540,000 $886,470,000 $953,222,000 $910,106,000 $799,038,000 $812,653,000 $837,049,000
Non Us $238,291,000 $240,222,000 $238,887,000 $174,503,000 $176,706,000 $144,327,000 $150,357,000 $138,728,000

By Product & Service (USD)

Component FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Product $1,084,744,000 $1,136,581,000 $1,125,046,000 $1,127,618,000 $1,086,770,000 $943,324,000 $962,936,000 $975,692,000
Gastrointestinal $259,788,000 $255,943,000 $231,610,000 $226,583,000 $204,559,000 $161,136,000 $172,908,000 $160,462,000
Womens Health $227,765,000 $236,831,000 $240,421,000 $251,351,000 $264,509,000 $268,097,000 $251,551,000 $258,479,000
Eye and Ear Care $142,939,000 $183,322,000 $179,423,000 $171,076,000 $163,449,000 $110,409,000 $112,156,000 $112,837,000
Dermatologicals $125,931,000 $128,947,000 $129,102,000 $123,741,000 $120,386,000 $107,083,000 $103,012,000 $97,972,000
Analgesics $113,936,000 $117,697,000 $117,451,000 $119,262,000 $119,323,000 $119,142,000 $114,007,000 $114,178,000
Cough and Cold $101,909,000 $106,214,000 $119,020,000 $126,988,000 $107,080,000 $70,641,000 $111,106,000 $103,123,000
Oral Care $101,051,000 $95,030,000 $96,305,000 $97,627,000 $97,521,000 $101,431,000 $93,205,000 $103,432,000
Other Otc $15,386,000 $13,778,000 $12,025,000 $11,097,000 $9,985,000 $5,426,000 $5,065,000 $5,483,000
Product And Service Other $3,961,000 $1,181,000 $311,000 $107,000 $42,000 $41,000 $74,000 $85,000
Household Cleaning Department — — — — — — $0 $19,811,000
Key facts CIK 1295947 CUSIP 74112D101 13F (30d) 40 filings 39 filers Visit website Investor relations